CAR-T therapy in Hematology
Koji Izutsu
2023/8/15
We have been conducting CAR-T therapy for B-cell lymphomas as clinical trials since 2017 and as a clinical practice since 2020. There are 3 CAR-T products for B-cell lymphomas and we conducted clinical development of these products in Japan. Currently, we are performing 3-5 cases of CAR-T therapy per months as clinical practice.
Candidates for CAR-T for lymphoma include patients with third line diffuse large B-cell lymphoma (DLBCL); second line DLBCL who are eligible for transplant and CR duration of <1 year or who are ineligible for transplant; third line follicular lymphoma. This new modality is expected to provide long-term benefit to at least a part of the patients for whom long-term survival could not be expected with conventional chemotherapy or hematopoietic stem cell transplantation.
